Olpasiran (formerly AMG 890) Drug Research Report 2024: A Small Interfering RNA Designed to Lower the Body's Production of Apolipoprotein - 7MM Market Size, Forecast, and Emerging Insights 2019-2032
April 16, 2024 04:39 ET
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Olpasiran Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."Olpasiran Market Size,...
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
April 09, 2024 08:30 ET
|
Tenax Therapeutics
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
April 06, 2024 16:16 ET
|
Novartis Pharma AG
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
April 05, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research...
Euroseas Ltd. Announces One-Year Time Charter Contract and Completion of Retrofits for its Intermediate Containership, M/V Synergy Antwerp
April 02, 2024 09:00 ET
|
Euroseas
ATHENS, Greece, April 02, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
March 28, 2024 08:30 ET
|
Tenax Therapeutics
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion...
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
March 26, 2024 14:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in AI-driven healthcare technology, today announced the launch of the DECIDE Registry, the largest prospective...
US Healthcare Information Exchange Market Outlook 2024-2029 - Federated Healthcare Model Dominates Market Share, Expected to Surge with Rising Digital Adoption and Investment
March 25, 2024 13:26 ET
|
Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "United States Healthcare Information Exchange - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019-2029" report has been...
Euroseas Ltd. Announces Completion of Retrofits of its Intermediate Containership, M/V Marcos V, Reducing the Vessel’s Carbon Footprint
March 21, 2024 09:00 ET
|
Euroseas
ATHENS, Greece, March 21, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne...
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
March 21, 2024 07:14 ET
|
Milestone Pharmaceuticals Inc.
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2...